The Trpm4 gene has recently been associated with several disorders, including cardiac conduction diseases and Brugada syndrome. Transient receptor potential member 4 (TRPM4) proteins constitute Ca 2+activated, but Ca 2+ -impermeable, nonselective cation channels and are expressed both in atrial and in ventricular cardiomyocytes. The physiological function of TRPM4 in the heart remains, however, incompletely understood.
S ympathetic stimulation of the heart through β-adrenergic receptors is a prominent extrinsic control mechanism of contractile force and cardiac function. 1, 2 Binding of (nor)epinephrine to β-adrenergic type 1 receptors leads to generation of cAMP that activates protein kinase A (PKA), leading to phosphorylation of several proteins involved in excitation-contraction coupling, including the L-type Ca 2+ channel, phospholamban, and troponin I. β-Adrenergic stimulation of the heart muscle leads to increased contractile force (inotropy), heart rate (chronotropy), and increased relaxation rate (lusitropy). 1, 2 In ventricular myocytes, the inotropic effect is mainly attributed to PKA-mediated increase in L-type Ca 2+ channelmediated Ca 2+ entry and subsequent Ca 2+ -induced Ca 2+ release (CICR), resulting in a larger Ca 2+ transient and stronger contraction. 1, 2 Furthermore, phosphorylation of phospholamban by PKA releases its tonic inhibition of the sarcoendoplasmic reticulum calcium transport ATPase pump, resulting in more Ca 2+ being sequestered into the sarcoplasmic reticulum (SR) and more Ca 2+ being available for subsequent release. In the same way, phospholamban phosphorylation also contributes to lusitropy because the increase in Ca 2+ flux from cytosol to SR accelerates relaxation of the myofilaments. PKA phosphorylation might also modulate Ca 2+ release from the SR through the ryanodine receptor. It was shown that Ca 2+dependent activation of the ryanodine receptor is increased on phosphorylation by PKA. 3 A global rise in [Ca] 2+ cyt is the direct activator of cardiac muscle contraction. The rate and the amount of Ca 2+ being released from the SR during excitation-contraction coupling are dependent on the amount of Ca 2+ entering the cell through L-type Ca 2+ channels. A larger (or longer) increase in [Ca] 2+ cyt will lead to stronger contractions. 4, 5 Defective intracellular Ca 2+ homeostasis January 17, 2014 is a central cause of contractile dysfunction and arrhythmias in failing myocardium. 6 An important determinant of the amplitude and duration of the Ca 2+ transient, and consequently contractile force, in cardiac myocytes is the shape of the action potential (AP) waveform. AP duration (APD) will affect the amount of Ca 2+ influx through the L-type Ca 2+ channel. 7 The cardiac AP is shaped by a complex choreography of opening and closing of several ion channels, including depolarizing voltage-gated Na + and Ca 2+ channels, and a range of repolarizing K + channels. 4, 8 In addition to voltage-gated ion channels, other types of ion channels that may contribute to the AP waveform were described in cardiac myocytes, including Ca 2+ -activated nonselective cation channels. 9 A candidate for this channel might be transient receptor potential member 4 (TRPM4), a member of the superfamily of transient receptor potential ion channels. 10, 11 TRPM4 has been suggested as the molecular counterpart of Ca 2+ -activated nonselective cation channels in cardiomyocytes. 12 TRPM4-like activity has been described in sinoatrial node cells, 12 and atrial myocytes from Trpm4 −/− mice display a shorter AP. 13 Interest in the physiological role of TRPM4 in the heart has further risen with the description of mutations in the TRPM4 gene that are linked to autosomal dominant forms of cardiac conduction diseases, including progressive familial heart block type I and Brugada syndrome. [14] [15] [16] Heterologous overexpression of mutant channels in human embryonic kidney cells indicates that these mutations can lead to increased or decreased expression and activity of TRPM4 proteins, [14] [15] [16] [17] which might contribute through an as yet unknown mechanism to the above-mentioned syndromes. Overall, the contribution of TRPM4 proteins to the dynamics of cytosolic Ca 2+ handling in ventricular cardiomyocytes and to contractility of the heart and its relevance during, for example, neurohumoral stress has not been elucidated to date.
The aim of our study was to investigate the functional role of the TRPM4 channel in ventricular cardiac myocytes using TRPM4-deficient mice. We used a multidisciplinary approach from live cell Ca 2+ imaging, patch-clamp electrophysiology, contractility recordings of isolated ventricular papillary muscle to in vivo measurements of ECG, and pressure-volume loops.
Methods
For this study, all experiments were performed with Trpm4 −/− mice, 11 backcrossed 8 generations in 129/SvJ background, which were compared with 129/SvJ wild-type (WT) mice. Preparation of cardiac tissue, expression analysis, microfluorimetric and electrophysiological recordings, in vivo pressure-volume loop analysis, in vitro contractility measurements, and telemetric ECG recordings were performed. All statistical analyses were performed using Statistica 6.0 (Statsoft, Tulsa, OK) or Origin (Microcal, USA) software. Data are expressed as mean±SEM. Differences between groups were compared by 1-way ANOVA followed by a least significant difference post hoc test or a Student t test. A detailed Methods section is available in the onlineonly Data Supplement.
Results

Cardiac Contractility in WT and Trpm4 −/− Mice
We have previously shown that TRPM4 proteins are expressed in ventricle and atria from adult mouse heart. 18 To test whether Trpm4 −/− mice display a cardiac phenotype, we studied left ventricular function in vivo using pressure-volume loop analysis of the cardiac cycle. Representative examples of measurements during preload reduction under basal conditions and after infusion of isoprenaline are shown in Figure 1A and 1B. As documented in Tables 1 and 2 , we found no difference between WT and Trpm4 −/− cardiac contractility parameters under basal conditions. However, infusion of ≤300 ng/ kg·min isoprenaline leads to a drastically stronger increase in stroke volume, cardiac output, stroke work, and preload recruitable stroke work in Trpm4 −/− compared with WT mice ( Figure 1C-1F ). Also, the increase in heart rate on isoprenaline infusion was slightly but significantly higher in Trpm4 −/− mice. Notably, when we compared isolated, spontaneously beating right atria, we found no difference in the chronotropic effect of β-adrenergic stimulation in vitro (Online Figure I) .
To relate this in vivo phenotype to the heart muscle, we performed contraction experiments with isolated left ventricular papillary muscle from WT and Trpm4 −/− hearts. As shown in Figure 2A and 2B, application of isoprenaline leads to a more robust increase in contraction strength in Trpm4 −/− papillary muscles compared with WT, whereas basal contraction strength is unaltered ( Figure 2C ). The sensitivity for isoprenaline was also not different between WT and Trpm4 −/− tissue ( Figure 2D ). To further compare contractile properties of the ventricular cardiac muscle between WT and Trpm4 −/− mice, we tested the force-frequency relationship, dependence of contraction strength on extracellular [Ca] 2+ , and postrest potentiation in both genotypes (Online Figure II) . In none of these experiments did we find differences between WT and Trpm4 −/− papillary muscle preparations.
Ca 2+ Transients in WT and Trpm4 −/− Ventricular Cardiomyocytes
Because CICR is the dose-dependent trigger for cardiac contraction, 4 we measured Ca 2+ transients in intact cardiomyocytes during field stimulation (rate=5 Hz; Figure 3A -3C). Online Table I summarizes our data. Under basal conditions, Ca 2+ transients were identical in WT and Trpm4 −/− myocytes, except for the width of the transient at 50% peak value, which was significantly decreased in Trpm4 −/− cells. When we compared WT and Trpm4 −/− cardiomyocytes, the effect of isoprenaline on the peak Ca 2+ level was significantly higher in Trpm4 −/− myocytes ( Figure 3C ). Notably, the lusitropic effect of β-adrenergic stimulation (ie, the acceleration of decay of the Ca 2+ transient after isoprenaline application) was not significantly different between Trpm4 −/− and WT myocytes ( Figure III ).
Voltage-Gated Ca 2+ Currents in WT and Trpm4 −/− Myocytes
Because the L-type Ca 2+ current is the trigger for excitationcontraction coupling and determines contraction strength, we performed an in-depth analysis of L-type Ca 2+ currents in primary cardiomyocytes from WT and Trpm4 −/− mice. Both under basal conditions and after β-adrenergic stimulation, voltage-gated L-type Ca 2+ currents were identical in WT and Trpm4 −/− cardiomyocytes with respect to peak current density, activation and inactivation characteristics, and recovery from inactivation. Results are depicted in Figure 3D and 3E and Online Figures IV and V.
Trpm4 Is Functionally Expressed in Mouse Ventricular Cardiomyocytes
Previous single-channel measurements had shown that TRPM4 proteins constitute a Ca 2+ -activated cation channel Tables 1 and 2 . January 17, 2014 in atrial myocytes. 13 Using laser-microdissected preparations, we can show Trpm4 expression unambiguously in left ventricular cardiomyocytes (Online Figure VI) . To analyze functional expression of TRPM4 in ventricular myocytes, we performed whole-cell patch-clamp experiments in isolated ventricular myocytes using intra-and extracellular solutions that minimized the activity of K + channels. Because TRPM4 is activated by cytosolic calcium, we hypothesized that TRPM4-mediated currents would be most prominent during (depolarization-induced) calcium transients. To test this, we applied a voltage-clamp protocol consisting of a 10-ms depolarization to +10mV, which induces CICR and a contraction of the myocyte, followed by a test step to either −80 or +80 mV ( Figure 4A -4D). The time course and amplitude of the global Ca 2+ transient evoked by these protocols were not different between WT and Trpm4 −/− myocytes ( Figure 4A and 4B; peak-∆F/F test pulse −80 mV: WT, 0.4±0.08; Trpm4 −/− , 0.4±0.1; n=18-20, respectively; test pulse +80 mV: WT, 0.4±0.1; Trpm4 −/− , 0.39±0.09; n=9-8, respectively). However, there were clear differences between Trpm4 −/− and WT myocytes in the amplitude and time course of the currents during the test steps to −80 and +80 mV ( Figure 4C and 4D). At −80 mV, inward tail currents recorded from Trpm4 −/− myocytes exhibited a lower amplitude and more rapid decay than those measured in WT myocytes ( Figure 4C and 4G). Fitting a mono-exponential function to this inward tail current yielded a time constant (τ) of 2.8±0.4 ms for WT versus 1.7±0.3 ms for Trpm4 −/− myocytes (n=18-20; P<0.05). Importantly, the difference between WT and Trpm4 −/− myocytes was no longer observed when 10 mmol/L EGTA was added to the pipette Figure 4E and 4G). Under this condition, the mono-exponential time constant of current decay was similar in WT and Trpm4 −/− myocytes and not different from the time constant measured in Trpm4 −/− myocytes under control conditions (τ WT =1.8±0.2 ms; τ Trpm4 −/− =1.5±0.1 ms; n=7). Taken together, these results indicate that TRPM4 contributes to the calcium-dependent component of the inward tail current after ventricular myocyte depolarization.
Similar differences between whole-cell currents in WT and Trpm4 −/− myocytes were observed when the 10-ms depolarization to +10 mV was followed by a further depolarizing test step to +80 mV. In response to this protocol, WT myocytes exhibited a clearly biphasic outward current at +80 mV, which consisted of a transient current component and a sustained current ( Figure 4D ), and could be fitted by a double exponential function with a rising and decaying exponential component. In contrast, the outward current in Trpm4 −/− myocytes lacked the transient outward component and was excellently fitted by a mono-exponential function ( Figure 4D ). These results suggest that the transient current component is critically dependent on TRPM4 expression. To extract the size and time course of the transient outward current component on a cell-to-cell basis, we fitted all current traces with a mono-exponential function forced through the current value at the end of the 20-ms voltage step to +80 mV (dotted trace in Figure 4D ) and compared the residual current (ie, the difference between the actual current and the monoexponential fit) in WT and Trpm4 −/− myocytes ( Figure 4F ). This is a valid approach because the mean current density at the end of the +80-mV step is identical between WT and Trpm4 −/− myocytes (WT, 6.81±0.6 pA/pF; Trpm4 −/− , 6.8±0.8 pA/pF; n=9-8, respectively). In WT myocytes, the residual current had a clear outward component, reaching a peak 5.0±0.3 ms (n=9) after depolarizing to +80mV, followed by a gradual decay. In contrast, the residual current in Trpm4 −/− myocytes showed no clear inward or outward component but centered around the abscissa. This was further quantified by determining the area under the curve for the residual current ( Figure 4G) . Importantly, the residual current in WT myocytes increased significantly when the amplitude of the Ca 2+ transient was increased because of stimulation with isoprenaline ( Figure 4G ). Taken together, these data indicate that TRPM4 is activated in a calcium-dependent manner on depolarization of ventricular myocytes. The electrogenic Na + /Ca 2+ exchanger, which is an important calcium extrusion mechanism in ventricular myocytes, is expected to contribute to membrane currents during calcium transients. 19, 20 To exclude that the above-described changes in current observed in Trpm4 −/− myocytes would be the mere consequence of altered Na + /Ca 2+ exchanger activity, we compared calcium transients and whole-cell currents induced by caffeine-evoked calcium release from the SR in WT and Trpm4 −/− ventricular myocytes. As documented in Online Figure VII , caffeine evoked Ca 2+ release and induced a membrane current in ventricular myocytes from both WT and Trpm4 −/− mice. The amplitude of the Ca 2+ transient, as well as the time course of current and calcium decay, was not different between both genotypes, indicating that Na + /Ca 2+ exchanger activity is not reduced in Trpm4 −/− ventricular myocytes. Notably, however, the peak inward current after caffeine stimulation was significantly reduced in Trpm4 −/− myocytes, which is in line with a contribution of TRPM4 to the inward current at the peak of the caffeine-induced calcium transient.
AP Analysis in Papillary Muscle From WT and Trpm4 −/− Mice
Our findings that TRPM4 contributes to whole-cell currents during depolarization-induced calcium transients suggested that TRPM4 may influence the shape of the AP in ventricular myocytes. To evaluate this, we used intracellular high-resistance microelectrodes to determine AP characteristics from paced left ventricular papillary muscle ( Figure 5A and 5B) . Online Table II summarizes properties of APs recorded at 5 Hz pacing rate. The resting membrane potential was not different between WT and Trpm4 −/− cardiomyocytes. Amplitude and upstroke velocity of the AP in WT and Trpm4 −/− cardiomyocytes were not significantly different. However, halfheight width, AP duration at 50% repolarization, and AP duration at 90% repolarization were significantly reduced in Trpm4 −/− myocytes. Notably, comparing ECG recordings from freely moving WT and Trpm4 −/− mice revealed no differences in any of the standard electrocardiographic intervals (Online Table III ).
To exclude that the activity of other membrane currents that are known to shape the membrane potential was altered in Trpm4 −/− mice, we performed electrophysiological recordings to compare the activity of the voltage-gated Na + current (Na V ), voltage-gated K + (K to and K SS ) currents, and inwardrectifying K + (K1) current between WT and Trpm4 −/− cardiac myocytes. Densities of these currents were identical in both groups ( Figure 5C -5F and Online Figure VIII ).
Whole-Genome Analysis of Gene Expression in WT and Trpm4 −/− Heart
Apart from the control experiments mentioned above, we performed a genome-wide analysis of gene expression in the heart of WT and Trpm4 −/− mice to analyze whether alterations in gene expression in Trpm4 −/− mice unrelated to the TRPM4 gene could be responsible for the observed phenotype. A list of upregulated and downregulated transcripts is presented in Online Tables IV and V. Overall, the level of upregulation and downregulation was limited (typically 2-fold), and none of the differentially expressed genes is known to be involved in excitation-contraction coupling or adrenergic signaling in the cardiac myocyte.
Nifedipine-Sensitive Currents During WT or Trpm4 −/− AP
The shape of the cardiac AP is an important determinant of the amount of Ca 2+ entering via L-type Ca 2+ channels, which has a profound effect on cardiac contraction strength. 7 To determine the consequence of the altered AP shape in TRPM4-deficient mice on L-type Ca 2+ current activation and Ca 2+ entry, we applied the average AP recorded at 5 Hz pacing rate from WT (WT-AP) and Trpm4 −/− (knockout-AP) papillary muscles as a command voltage to single WT and Trpm4 −/− cardiomyocytes. Figure 6A and 6B illustrates the simultaneous measurement of membrane current and [Ca] 2+ cyt under conditions that block K + channel activity. After the initial peak, representing the Na V current, a smaller shoulder current can be distinguished, which significantly increases in amplitude when 1 μmol/L isoprenaline is applied. This component can be completely blocked with 1 μmol/L nifedipine ( Figure 6B ) and thus represents the activity of L-type Ca 2+ channels. When we applied the WT-AP and the knockout-AP waveform as a voltage protocol to the same cell and compared the nifedipine-sensitive current, the knockout-AP consistently resulted in increased nifedipine-sensitive calcium current compared with the WT-AP, both under basal conditions and after application of isoprenaline (1 μmol/L; Figure 6A and 6B). Identical results were obtained when both AP waveforms were applied to Trpm4 −/− myocytes. Figure 6C and 6D illustrates the area under the curve of the nifedipine-sensitive current under basal conditions and in the presence of isoprenaline in response to WT-AP and knockout-AP when applied to the same WT or Trpm4 −/− myocyte. Taken together, these results demonstrate that the more rapid AP repolarization in Trpm4 −/− cardiomyocytes leads to increased L-type Ca 2+ channel activation and Ca 2+ entry.
Discussion
In this study, we have provided the first direct evidence for functional expression and physiological relevance of the Ca 2+ -activated nonselective cation channel TRPM4 in mouse ventricular muscle. First, using in vivo pressure-volume loop measurements, we found no difference in cardiac output, stroke work, and preload recruitable stroke work between WT and Trpm4 −/− mice under basal conditions. However, Trpm4 −/− mice exhibited a much more pronounced inotropic response to β-adrenergic stimulation, including a stronger increase in preload recruitable stroke work. Furthermore, the contractile force of isolated left ventricular papillary muscle of Trpm4 −/− mice showed a more robust increase on stimulation with isoprenaline compared with WT mice. Second, using combined calcium imaging and patch-clamp recordings, we were able to dissect for the first time a Ca 2+ -activated whole-cell current in WT ventricular myocytes that is specifically lacking in Trpm4 −/− mice myocytes. This TRPM4-dependent current is activated by depolarization-induced calcium transients, suggesting that it may modulate AP repolarization. Third, in line with the properties of the TRPM4-dependent whole-cell currents, we observed that APs recorded from Trpm4 −/− ventricular myocytes exhibit a significantly faster repolarization phase than WT controls. Importantly, we demonstrate that this shorter AP waveform results in increased Ca 2+ influx through nifedipine-sensitive L-type calcium channels. Taken together, these data are fully consistent with a model in which TRPM4 (1) is activated by the rise in intracellular calcium during a ventricular AP, (2) acts as a brake on AP repolarization, and (3) thereby reduces the driving force for Ca 2+ influx through L-type Ca 2+ channels and thus contractile force. This contribution of TRPM4 is specifically important during β-adrenergic stimulation when the Ca 2+ current and the Ca 2+ transient are strongly enlarged, as discussed below. Our data suggest that TRPM4 is a novel pharmacological target to achieve increased β-adrenergic inotropy.
In vivo pressure-volume loop measurements demonstrate a stronger increase in cardiac output, stroke work, and preload recruitable stroke work specifically after β-adrenergic stimulation in Trpm4 −/− mice. Notably, also the heart rate after βadrenergic stimulation is slightly increased in Trpm4 −/− mice. It is unclear how this arises because this effect is absent in isolated right atrium. Especially, the difference in preload recruitable stroke work is important because it is independent of the preload of the heart 21, 22 and illustrates that the intrinsic inotropic status of the Trpm4 −/− muscle is enhanced compared with WT after β-adrenergic stimulation. In accordance with For clarity, the fast voltage-gated Na + current (Na V ) component is cut. C, Representative traces from currents recorded at −80 mV as in A. The colored lines represent the exponential fit of these traces. Time 0 equals 1 ms after the end of the step to +10 mV as in A and B. D, Representative traces from currents recorded at +80 mV as in B. The full colored lines represent the exponential fit of these traces. The dotted green line represents a mono-exponential fit of the wild-type (WT) trace as described in the text. Time 0 equals 1 ms after the end of the step to this, contractility measurements with isolated papillary muscle from left ventricle show that the increased contractility can be delineated to an inherent property of the Trpm4 −/− cardiac muscle. The contractility data correspond well with measurements of the global intracellular Ca 2+ transient in contracting cardiomyocytes. We found after β-adrenergic stimulation, but not under basal conditions, that the global [Ca] 2+ cyt is larger in Trpm4 −/− myocytes. Considering the highly nonlinear relationship between [Ca] 2+ cyt and sarcomere contraction strength (see for instance), 23 even a limited increase in the Ca 2+ transient will have a profound effect on contraction strength.
We have shown previously that TRPM4 proteins are present in ventricle and atrium of mouse heart. 18 To characterize the TRPM4 current in ventricular myocytes in a physiologically relevant manner, we performed whole-cell patch-clamp experiments. Current recordings of WT and Trpm4 −/− myocytes during a triggered Ca 2+ release event reveal the time course and amplitude of a TRPM4-dependent current in isolated ventricular myocytes. This current seems transiently active during the global Ca 2+ transient, with a maximal current density in the range of −5 pA/pF at −80 mV. Whole-cell properties of TRPM4 channels in excitable cells have not been determined to date. However, in overexpression systems it has been shown that TRPM4 activity even during a sustained Ca 2+ increase is transient and depends on, for example, the phosphatidyl inositol 4,5 bisphosphate level in the cell. 24 The time course of the TRPM4 current we report here is similar to that reported for the highly related TRPM5 channel (which has similar properties as TRPM4 but is not present in the heart) in pancreatic β-cells. 25 Recording of TRPM4-dependent single-channel currents in cell-free patches from atrial myocytes required, besides pretreatment of cells with phorbol-12-myristate-13-acetate, 1 mmol/L Ca 2+ at the intracellular side of the membrane, 13 indicating that the Ca 2+ sensitivity of the TRPM4 current is relatively low in myocytes and that TRPM4 will likely follow the increase in subcellular Ca 2+ level near the Ca 2+ release sites rather than the global Ca 2+ transient during excitation-contraction coupling. The time course of TRPM4 activity in myocytes closely resembles the time course of the subcellular Ca 2+ level in stimulated myocytes, which decays from an estimated level of 10 μmol/L within 10 ms to a concentration of ≈1 μmol/L. 19 Considering that TRPM4 is a Ca 2+ -activated nonselective cation channel, our data suggest that TRPM4 would be active during and could shape the repolarization phase of the AP. We found that TRPM4 deletion shortens the time for 50% and 90% repolarization (AP duration at 50% repolarization and AP duration at 90% repolarization) of the AP. We can exclude that the intrinsic properties of the main currents during the cardiac AP are altered in Trpm4 −/− myocytes, and our results are consistent with a previous report on atrial myocytes from an independent Trpm4 −/− mouse line. 13 How could TRPM4 influence β-adrenergic inotropy? From the literature it is well known that APD can determine the amplitude of L-type Ca 2+ currents. 7 A strong reduction in APD would reduce the probability of L-type Ca 2+ channel opening and its mean open time by accelerating channel closure via deactivation. However, a small reduction in APD and rapid repolarization of the AP, as we report in Trpm4 −/− mice, ensure a relatively large I Ca,L because the driving force for Ca 2+ entry through the L-type Ca 2+ channels that remain open during the repolarization phase will be comparably higher. 7 Consistent with this idea, we found that the nifedipine-sensitive current during an average AP recorded from WT or Trpm4 −/− myocytes is increased during the Trpm4 −/− AP. Nifedipine blocks L-type Ca 2+ channels, but will also prevent CICR and reduce the activity other Ca 2+ -dependent currents, such as TRPM4, Na + /Ca 2+ exchanger, and Ca 2+ activated Cl − channels, in our experiments. However, our results were essentially identical when we applied the WT or Trpm4 −/− AP either to WT or Trpm4 −/− myocytes. This indicates that the AP shape per se is responsible for the increase in nifedipine-sensitive current and is independent of the genotype of the myocytes.
As the AP repolarizes, the driving force for I Ca,L increases, L-type Ca 2+ channel openings provide larger unitary currents and hence are more effective in promoting the opening of ryanodine receptors, and release is more effectively triggered. 7 From our data, an increased [Ca] 2+ cyt level in Trpm4 −/− myocytes is only apparent after β-adrenergic stimulation. This is not unexpected if we consider that the gain of CICR (ie, the ratio of the amount of Ca 2+ released during a Ca 2+ transient to the amount of the trigger Ca 2+ ) 26 is increased after β-adrenergic stimulation. 27 The probability of a single L-type Ca 2+ channel activating an individual SR Ca 2+ release unit can be described as the product of a coupling factor, which is proportional to the square of the unitary I Ca,L , and the open channel probability of the L-type Ca 2+ channel. 28 After β-adrenergic stimulation, the open probability of the L-type Ca 2+ channel will be increased, implicating that especially under these conditions the relationship between SR Ca 2+ release and trigger I Ca,L will be steep and that a limited increase in I Ca,L , as we report here, will have a profound effect on CICR but not under basal conditions. Increased L-type Ca 2+ currents and [Ca] 2+ cyt transients when the AP is shortened to a similar extent as we observed in Trpm4 −/− myocytes can be reproduced in an established mathematical model of the ventricular AP and intracellular Ca 2+ dynamics from mouse myocytes. 29 It should be noted, however, that in the current mathematical models of the ventricular AP in various species, a Ca 2+ -activated nonselective cation current is not included. Our results suggest that inclusion of a TRPM4-like current as described in this study will improve the predictive power of these models. Previously, we could show that TRPM4 depolarizes the membrane potential on an increase in the intracellular Ca 2+ concentration and limits the driving force for Ca 2+ entry in primary nonexcitable cells, such as mast cells. 11 Here, we show for the first time the effect of TRPM4 activity on Ca 2+ signals in excitable cells. Our data +10 mV as in A and B. E, Representative current traces in response to a protocol as in A, with 10 mmol/L EGTA in the pipette solution. F, Representative examples of the residual current calculated from a mono-exponential fit of WT and Trpm4 −/− traces as in D. See text for further details. G, Left, Mean values of the time constant for exponential decay of currents at −80 mV under basal conditions and in the presence of 10 mmol/L EGTA in the pipette solution. Middle, Area under the curve of the residual current, as in F, under basal conditions and in the presence of isoprenaline (ISO; 1 μmol/L). Right, Mean current densities at 5 ms after the +10-mV step with 10 mmol/L EGTA in the pipette or in the presence of 1 μmol/L ISO as indicated (n, numbers are in brackets). CTRL indicates control. suggest that the role of TRPM4 can be generalized to a negative modulator of intracellular Ca 2+ signaling through limiting the driving force for Ca 2+ influx.
Taken together, our data point at a novel mechanism to achieve increased β-adrenergic inotropy of the heart muscle. Other mouse models with a comparably small decrease of APD exist, such as Hcn3 −/− mice, 30 but to our knowledge β-adrenergic inotropy has not been tested in these mice. Recently, 9-phenanthrol has received much attention as a TRPM4-specific antagonist. However, this compound also affects voltage-gated Ca 2+ and K + channels in primary myocytes, 31 which limits its usefulness as an agent to delineate the pharmacological potential of TRPM4 in living mice.
It is tempting to speculate that TRPM4 is an interesting drug target in syndromes of acute heart failure. An important feature of this condition is the strong upregulation of neurohumoral factors including the renin-angiotensin-aldosterone system and the adrenergic nervous system. 32 Our results support the hypothesis that blockade or gene knockdown of the TRPM4 channel could represent a novel mechanistic approach to modify contractile strength in patients with acute heart failure who already exhibit increased plasma catecholamine levels. Figure 5 . Transient receptor potential member 4 (TRPM4) contributes to the ventricular action potential. A, Representative traces of membrane potential recordings from wild-type (WT) mouse ventricular papillary muscle (pacing rate: 5 Hz). B, Overlay of the mean action potential from WT and Trpm4 −/− papillary muscle (pacing rate: 5 Hz; WT: n=26; Trpm4 −/− : n=24). C-F, Comparison of voltage-gated Na + current (Na V ), voltage-gated K + (K to and K ss ), and inwardrectifying K + (K1) currents from WT and Trpm4 −/− myocytes. For representative current traces, see Online Figure VII . All panels depict mean±SEM (C-F, n=12 for both genotypes, from 3 mice each; no significant differences between genotypes). 
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None. Figure 6 . Action potential induced nifedipine-sensitive Ca 2+ currents in wild-type (WT) and Trpm4 −/− cardiomyocytes. A, Representative current traces when an average WT action potential (AP; black trace) and a knockout (KO)-AP (red trace) were applied to a WT myocyte in the absence (left) or presence (right) of isoprenaline (ISO, 1 μmol/L). Note the increase in the L-type Ca 2+ current component under ISO conditions, which can be blocked with nifedipine (10 μmol/L). The horizontal dotted line represents the zero current level. C-D, Mean±SEM values for area under the curve (AUC) of the nifedipine-sensitive current derived from experiments as in B (n=15 for both genotypes, *P<0.01) when the WT-AP and KO-AP are applied to a WT myocyte (C) or a Trpm4 −/− myocyte (D). CTRL indicates control.
